

Signal Law Group Issues Vigilant Risk Score™ Bulletin on Cue Biopharma, Inc. (CUE) and Flags Risk Indicators

NEW YORK, NY, June 15, 2026 – Signal Law Group has issued a Vigilant Risk Score™ bulletin on Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company, after flagging elevated securities disclosure-related risk indicators. The bulletin notes Cue Biopharma's April 2026 1-for-30 reverse stock split undertaken to regain Nasdaq compliance following sustained share price declines and financial difficulties, and references ongoing financial and strategic pressures, including limited cash, continued losses, and dependence on external clinical data and future financing. These factors contribute to a current Vigilant Risk Score™ assessment that highlights potential exposure for investors and stakeholders.

Investigation Overview

Signal Law Group initiated this bulletin in response to Cue Biopharma, Inc.'s 1-for-30 reverse stock split in April 2026 following a period of sustained share price declines and financial strain. The firm is reviewing whether the company's securities disclosures adequately reflected its financial condition, strategic risks, and reliance on external clinical data and future financings.

The focus of the forensic review is on securities disclosure risk indicators, including how Cue Biopharma has described its shift toward autoimmune and inflammatory disease therapies and its ongoing liquidity and loss profile. Signal is also analyzing whether public statements and filings sufficiently captured the implications of concentrated pipeline risk and the need for additional capital on existing investors and other stakeholders.

The current Vigilant Risk Score™ for Cue Biopharma, Inc. is 65 | Yellow, with an Event Momentum Signal (EMS) characterized as Building and a Legal Risk Indicator (LRI) assessed as Forming.

Company Overview

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing therapies targeting autoimmune and inflammatory diseases. In April 2026, the company executed a 1-for-30 reverse stock split aimed at regaining compliance with Nasdaq listing standards after sustained share price declines and financial challenges.

The company faces ongoing headwinds, including limited cash resources, continued operating losses, and strategic risks associated with dependence on external clinical data and the need for future financing. These dynamics shape the risk environment for investors as Cue Biopharma advances its evolving therapeutic portfolio.

Scope of Review

The scope of Signal Law Group's review centers on securities_disclosure issues related to Cue Biopharma, Inc. Specifically, the forensic team is examining: (1) the transparency and completeness of disclosures around the April 2026 1-for-30 reverse stock split and efforts to regain Nasdaq compliance; (2) representations regarding the company's financial condition, including cash runway, continued losses, and the need for future capital; and (3) disclosure of strategic and operational risks tied to dependence on external clinical data, portfolio shifts toward autoimmune and inflammatory disease therapies, and potential dilution or other impacts on existing investors.

"Our review is focused on whether Cue Biopharma's public disclosures have kept pace with its evolving financial condition and strategic risk profile, particularly around the April 2026 reverse stock split and ongoing funding needs. We are analyzing how these dynamics were communicated to investors under our Vigilant Risk Score framework to assess potential exposure and emerging risk patterns." said Lou Schwartz, Chief Forensic Officer of Signal Law Group.

No Legal Action Statement

No legal action has been initiated by Signal Law Group at this time. This bulletin reflects an ongoing structured forensic review and is not a determination of wrongdoing. Signal will evaluate next steps based on data development, regulatory response, and applicable law.

Why this matters: Cue Biopharma, Inc.'s combination of a recent 1-for-30 reverse stock split, sustained losses, and limited cash heightens sensitivity to how risks and future financing needs are communicated to the market. Investors in clinical-stage biopharmaceutical companies can be particularly exposed when business viability depends on external clinical data and ongoing access to capital. The securities_disclosure issues under review go directly to whether stakeholders had clear visibility into these pressures as the company shifted its portfolio toward autoimmune and inflammatory disease therapies. The current Vigilant Risk Score™ of 65 | Yellow reflects these elevated but still developing risk indicators.

Public Research Profile

Signal Law Group has launched a dedicated public research profile for this matter. Individuals may follow updates and submit information confidentially. Data submitted through the research portal may contribute to Signal's ongoing forensic analysis and clustering review.

[View Investigation](#)

[Submit Information](#)

Video Overview

A short video outlining the scope of the bulletin and the Vigilant Risk Score™ framework is available here:

[Watch Video](#)

FAQ

Q: What is the Vigilant Risk Score™ (VRS™)?

A: The Vigilant Risk Score™ is Signal Law Group's forensic analytics model designed to evaluate risk indicators associated with potential consumer liability exposure, using structured signals such as complaint clustering trends, disclosure consistency, and subscription representation patterns.

Q: What does "elevated indicators" mean in this bulletin?

A: It means the model's risk thresholds were met based on the inputs analyzed, suggesting patterns that merit further review. It is not a legal finding and not a determination of wrongdoing.

Q: Is Signal Law Group suing Cue Biopharma, Inc.?

A: No. Signal Law Group has not initiated legal action at this time. The bulletin reflects an ongoing forensic review.

Q: What is the scope of Signal's forensic review here?

A: The review is focused on securities_disclosure issues, including how Cue Biopharma, Inc. described its April 2026 1-for-30 reverse stock split and efforts to regain Nasdaq compliance, as well as its financial condition and ongoing need for capital. Signal is also examining disclosures regarding strategic and clinical risks associated with the company's shift toward autoimmune and inflammatory disease therapies and its reliance on external clinical data.

Q: How can someone share information with Signal Law Group?

A: Individuals can submit information confidentially through the public research profile.

Q: How will submitted information be used?

A: Submissions may be used to inform Signal's ongoing analysis, including evaluating whether reported issues cluster in ways that suggest repeatable patterns. Signal may also review publicly available materials related to the submission where appropriate.

Q: Will Signal Law Group provide updates?

A: Yes. Signal intends to publish periodic bulletins and updates as the analysis develops and as relevant data signals evolve.

About Signal Law Group

Signal Law Group is a New York-based research and investigations firm focused on identifying recurring corporate conduct patterns across consumer, financial, and technology sectors. The firm applies structured forensic analytics, including the Vigilant Risk Score™ methodology, to detect measurable risk indicators and emerging patterns that may warrant further review. Signal Law Group also makes certain analytical dashboards and monitoring outputs available to select institutional stakeholders under structured arrangements.

Media Contact

Signal Law Group

New York, New York

info@signallawgroup.com

www.signallawgroup.com

This bulletin is based on information believed to be reliable as of the date of publication. Signal Law Group does not undertake any obligation to update this bulletin. All statements other than statements of historical fact may be considered forward-looking and are subject to uncertainties and risks that could cause actual outcomes to differ. This document is provided for informational purposes only and does not constitute legal advice, investment advice, or a recommendation regarding any security, strategy, or company. Readers should conduct their own analysis and consult with qualified professionals before making any investment or legal decisions. Signal Law Group makes no representation or warranty, express or implied, as to the accuracy, completeness, or fitness of the information for any purpose.